background
fatal
pneumonia
attribut
human
coronavirus
hcov
hematopoiet
cell
transplant
hct
recipi
report
systemat
studi
possibl
role
hcov
lower
respiratori
tract
diseas
lrtd
hct
hematolog
malign
hm
patient
limit
method
conduct
retrospect
review
hcthm
patient
hcov
detect
bronchoalveolar
lavag
bal
hcov
strain
identifi
frozen
bal
sampl
use
strainspecif
pcr
mortal
rate
compar
among
hct
recipi
lrtd
caus
hcov
respiratori
syncyti
viru
rsv
influenza
flu
parainfluenza
viru
piv
without
respiratori
viral
copathogen
multivari
cox
regress
analysi
result
identifi
case
hcov
bal
tabl
among
sampl
avail
overal
case
requir
oxygen
therapi
diagnosi
case
die
within
day
diagnosi
twentyon
case
respiratori
pathogen
detect
includ
virus
n
fungi
n
bacteria
n
mortal
rate
patient
similar
without
copathogen
pvalu
multivari
cox
regress
mortal
adjust
cell
sourc
copathogen
neutrophil
lymphocyt
monocyt
use
diagnosi
steroid
use
respiratori
virus
hcov
rsv
flu
piv
carri
adjust
hazard
ratio
hcov
lrtd
overal
mortal
ci
pvalu
rsv
lrtd
refer
conclus
hcov
lrtd
hcthm
patient
associ
high
requir
mortal
mortal
associ
hcov
lrtd
hct
recipi
similar
seen
respiratori
viral
pathogen
includ
rsv
flu
piv
disclosur
j
englund
pfizer
consult
investig
research
support
speaker
honorarium
gilead
consult
investig
consult
fee
research
support
glaxosmithklin
investig
member
data
safeti
monitor
board
hourli
payment
dsmb
work
research
support
alio
investig
research
support
roch
investig
research
support
